ViaDerma Announces Intent to Launch a New Minoxidil Hair Regrowth Product
ViaDerma Announces Intent to Launch a New Minoxidil Hair Regrowth Product
The global hair restoration market is expected to reach $13.6 billion by 2028
预计到2028年，全球头发修复市场将达到136亿美元
LOS ANGELES, March 08, 2023 (GLOBE NEWSWIRE) -- ViaDerma, Inc. (OTC Pink: VDRM) is pleased to announce their plans to launch a new hair regrowth product using Minoxidil (topical route). The company will incorporate their proprietary, patent-pending dual carrier transdermal delivery technology with Minoxidil to create their new hair regrowth product.
洛杉矶，2023年3月8日（GLOBE NEWSWIRE）——ViaDerma, Inc.（场外交易代码：VDRM）欣然宣布，他们计划推出一款使用Minoxidil（外用途径）的新型头发再生产品。该公司将把他们专有的、正在申请专利的双载体透皮给药技术与Minoxidil相结合，开发新的头发再生产品。
ViaDerma's unique transdermal delivery system facilitates the transfer of chemicals through the stratum corneum, the outermost layer of the skin with a diffusion constant that is 10,000x higher than other products on the market. This allows much more of the active ingredient to be absorbed into the skin and work better and faster, often producing significantly better results than traditional topical treatments. Previous testing conducted by ViaDerma has yielded exceptional results at regrowing hair.
ViaDerma 独特的透皮输送系统促进了化学物质通过角质层的转移，角质层是皮肤的最外层，其扩散常数比市场上其他产品高 10,000 倍。这样可以让更多的活性成分被皮肤吸收，效果更好、更快，通常比传统的局部治疗效果要好得多。ViaDerma先前进行的测试在头发再生方面取得了非凡的结果。
A recently published report showed the global Minoxidil market size was valued at USD 1.038 billion in 2022 and is expected to expand at a CAGR of 5.48% during the forecast period, reaching USD 1.43 billion by 2028. The global hair restoration market as a whole which includes surgical and noninvasive treatments is expected to reach USD 13.6 billion by 2028, according to this research report by Grand View Research. Minoxidil is the active ingredient in several top selling hair regrowth products including Rogaine, Rogaine Extra Strength and Lipogaine.
最近发布的一份报告显示，2022年全球米诺地尔市场规模为10.38亿美元，预计在预测期内将以5.48％的复合年增长率增长，到2028年达到14.3亿美元。根据Grand View Research的这份研究报告，包括手术和非侵入性治疗在内的整个全球头发修复市场预计到2028年将达到136亿美元。米诺地尔是几种最畅销的头发再生产品的活性成分，包括Rogaine、Rogaine Extranght和Lipogaine。
ViaDerma's President & CEO, Dr. Chris Otiko said, "We are very excited to announce these plans for our new product and to enter this rapidly expanding industry. Our objective is to create the best hair regrowth product on the market."
ViaDerma总裁兼首席执行官克里斯·奥蒂科博士说：“我们很高兴宣布我们的新产品计划并进入这个快速发展的行业。我们的目标是创造市场上最好的头发再生产品。”
FDA registration of the product is expected to be completed within the next 90 days. The company expects to have the new product on the market later this year.
该产品的FDA注册预计将在接下来的90天内完成。该公司预计新产品将于今年晚些时候上市。
About ViaDerma, Inc.
ViaDerma, Inc. (OTC: VDRM) is a publicly traded specialty pharmaceutical company committed to bringing new products to market and licensing its innovative technology to current leaders in the pharmaceutical industry in a wide variety of therapeutic areas. For more information, visit:
Any forecast of future performance is a "forward looking statement" under securities laws. Such statements are included to allow potential investors the opportunity to understand management's beliefs and opinions with respect to the future so that they may use such beliefs and opinions as one factor among many in evaluating an investment.
关于 ViaDerma, Inc.
ViaDerma, Inc.（场外交易代码：VDRM）是一家上市的专业制药公司，致力于将新产品推向市场，并将其创新技术许可给制药行业各个治疗领域的现任领导者。欲了解更多信息，请访问：
根据证券法，任何对未来表现的预测都是 “前瞻性陈述”。纳入此类陈述是为了让潜在投资者有机会了解管理层对未来的信念和看法，这样他们就可以将这些信念和观点用作评估投资的众多因素之一。
Contact information:
Investor Relations
Email: ir@viaderma.com
Phone: 310-734-6111
Follow ViaDerma on Twitter:
Follow ViaDerma on Facebook:
联系信息：
投资者关系
电子邮件：ir@viaderma.com
电话：310-734-6111
在推特上关注 ViaDerma：
在 Facebook 上关注 ViaDerma：